Getting (Approximately) to Yeson Nondebtor Releases in MassTort Cases After Purdue Pharma

In a recent article for the American Bankruptcy Institute Journal, Doug Candeub, Counsel at Morris James, discusses the potential effects of the U.S. Supreme Court's decision in Purdue Pharma on future mass tort Chapter 11 bankruptcy cases. 

Getting (Approximately) to Yes on Nondebtor Releases in Mass Tort Cases After Purdue Pharma examines how the ruling limits nonconsensual nondebtor releases—previously a key tool in resolving mass tort bankruptcies.

The Purdue Pharma decision, with its split 5-4 ruling, effectively disallows the blanket release of third-party nondebtors from creditor claims. In his article, Candeub highlights the potential challenges this presents for Chapter 11 practitioners, particularly in cases involving large numbers of claimants. He also explores alternative solutions, such as consent-based releases and insurance buyback agreements, which may offer new strategies in light of the ruling.

This important analysis offers valuable insights for those navigating mass tort bankruptcies in the post-Purdue Pharma landscape.

Click here to read full article.